.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
US Department of Justice
Queensland Health
Harvard Business School
Moodys
Farmers Insurance
Express Scripts
McKesson
Boehringer Ingelheim
Cerilliant

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,415,053

« Back to Dashboard

Which drugs does patent 9,415,053 protect, and when does it expire?


Patent 9,415,053 protects XARELTO and is included in one NDA. There has been one Paragraph IV challenge on Xarelto.

This patent has thirty-seven patent family members in thirty-four countries.

Summary for Patent: 9,415,053

Title:Solid, orally administrable pharmaceutical composition
Abstract: The present invention relates to a process for the preparation of a solid, orally administrable pharmaceutical composition, comprising 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin- -5-yl}-methyl)-2-thiophenecarboxamide in hydrophilized form, and its use for the prophylaxis and/or treatment of diseases.
Inventor(s): Benke; Klaus (Bergisch Gladbach, DE)
Assignee: Bayer Intellectual Property GmbH (Monheim, DE)
Application Number:14/250,863
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Process; Dosage form; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Janssen PharmsXARELTOrivaroxabanTABLET;ORAL022406-001Jul 1, 2011RXYesNo► Subscribe► SubscribeYREDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM► Subscribe
Janssen PharmsXARELTOrivaroxabanTABLET;ORAL022406-001Jul 1, 2011RXYesNo► Subscribe► SubscribeYTREATMENT OF PULMONARY EMBOLISM (PE)► Subscribe
Janssen PharmsXARELTOrivaroxabanTABLET;ORAL022406-001Jul 1, 2011RXYesNo► Subscribe► SubscribeYTREATMENT OF DEEP VEIN THROMBOSIS (DVT)► Subscribe
Janssen PharmsXARELTOrivaroxabanTABLET;ORAL022406-001Jul 1, 2011RXYesNo► Subscribe► SubscribeYREDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM► Subscribe
Janssen PharmsXARELTOrivaroxabanTABLET;ORAL022406-001Jul 1, 2011RXYesNo► Subscribe► SubscribeYPROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)► Subscribe
Janssen PharmsXARELTOrivaroxabanTABLET;ORAL022406-002Nov 4, 2011RXYesNo► Subscribe► SubscribeYREDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM► Subscribe
Janssen PharmsXARELTOrivaroxabanTABLET;ORAL022406-002Nov 4, 2011RXYesNo► Subscribe► SubscribeYTREATMENT OF PULMONARY EMBOLISM (PE)► Subscribe
Janssen PharmsXARELTOrivaroxabanTABLET;ORAL022406-002Nov 4, 2011RXYesNo► Subscribe► SubscribeYPROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)► Subscribe
Janssen PharmsXARELTOrivaroxabanTABLET;ORAL022406-002Nov 4, 2011RXYesNo► Subscribe► SubscribeYREDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM► Subscribe
Janssen PharmsXARELTOrivaroxabanTABLET;ORAL022406-002Nov 4, 2011RXYesNo► Subscribe► SubscribeYTREATMENT OF DEEP VEIN THROMBOSIS (DVT)► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 9,415,053

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany103 55 461Nov 27, 2003

Non-Orange Book Patents for Patent: 9,415,053

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,402,851Process for the preparation of a solid, orally administrable pharmaceutical composition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,415,053

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina047844► Subscribe
Argentina104840► Subscribe
Austria385782► Subscribe
Australia2004305226► Subscribe
BrazilPI0416404► Subscribe
Canada2547113► Subscribe
China1886120► Subscribe
Colombia5690540► Subscribe
Cuba23551► Subscribe
Cyprus1107369► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Teva
Medtronic
Julphar
Accenture
Moodys
Dow
Colorcon
Mallinckrodt
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot